Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Nov 26, 2024

SELL
$2.94 - $5.23 $106,575 - $189,587
-36,250 Closed
0 $0
Q1 2022

Nov 22, 2024

SELL
$4.07 - $10.6 $61,050 - $159,000
-15,000 Closed
0 $0
Q4 2021

Nov 22, 2024

BUY
$8.96 - $16.31 $134,400 - $244,649
15,000 New
15,000 $156 Million
Q1 2021

Nov 22, 2024

SELL
$16.59 - $33.89 $340,924 - $696,439
-20,550 Reduced 57.81%
15,000 $429 Million
Q3 2020

Nov 22, 2024

BUY
$34.44 - $43.75 $1.22 Million - $1.56 Million
35,550 New
35,550 $1.96 Billion
Q4 2019

Nov 22, 2024

BUY
$46.96 - $61.67 $1.67 Million - $2.19 Million
35,550 New
35,550 $3.14 Billion
Q2 2019

Nov 22, 2024

SELL
$75.84 - $105.21 $265,440 - $368,235
-3,500 Reduced 8.96%
35,550 $4.4 Billion
Q1 2019

Nov 22, 2024

BUY
$64.44 - $104.11 $2.52 Million - $4.07 Million
39,050 New
39,050 $5.98 Billion
Q4 2018

Nov 26, 2024

BUY
$59.1 - $93.26 $2.14 Million - $3.38 Million
36,250 New
36,250 $3.53 Billion

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $585M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.